Muhammad Junaid Tariq

POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) syndrome is a rare multisystem disorder where early identification is essential for better long term outcomes. Yet it is often misdiagnosed. Gonçalves et al review the condition here: jnnp.bmj.com/content/early/… And this is a related editorial: jnnp.bmj.com/content/early/…

From NOS to a genomic informed category in DLBCL. Will we finally reach the point where biology can guide truly personalized treatment for our patients?

As BsAbs move into earlier lines, infection risk is the elephant in the room! Kim et al. @BloodAdvances: 75% cumulative infection rate at 24 mo. Neutropenia and low IgG drove risk, early steroids did not. IgG monitoring and timely IVIG remain key! doi.org/10.1182/blooda…

Original observation from a remarkable City of Hope team: Fahey, Rahbar, Blume, Forman, Beutler… Microcytosis in Hodgkin lymphoma → unbalanced globin synthesis → reversible with treatment Still relevant today. 📚 #Hematology #hemetwitter

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study ashpublications.org/blood/article-…

Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma onlinelibrary.wiley.com/doi/abs/10.100…

FDA approvals of drugs for myeloma since 2006. Who could argue that this is not a story of success? This shows the benefit of the Accelerated Approval Pathway. The two drugs withdrawn had minimal impact on safety or outcomes. What a privilege to be part of this era. #myeloma

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party @BloodPortfolio ashpublications.org/blood/article/…

#Hematology Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers #lymsm ashpublications.org/bloodadvances/…

New anatomic classification R/R SCNSL - 162 pts, 42 with both CNS+systemic dx - leptomeningeal dx = inferior OS in MV model - 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve) Useful schema in future trials. #lymsm onlinelibrary.wiley.com/doi/10.1002/ho…

Glofitamab CNS penetration @BloodAdvances - 8 pts with PCNSL/SCNSL, 7 LBCL, 1 BL - 3/8 CRS (all G1-2), no ICANS - 7/8 had response (4 CR, 3 PR) - both PCNSL pts had durable CRs with glofi monotx - CSF: +glofi with anti-B-NHL activity in vitro Good option as bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm ashpublications.org/bloodadvances/…

In a competitive job market, the grass is always greener somewhere, and there is a lot of grass out there at the moment. One component of job satisfaction is, of course, attitude. benwhite.com/misc/job-satis…

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma ⁦@BloodAdvances⁩ American Society of Hematology ashpublications.org/bloodadvances/…

1/4 REACTIVE THROMBOCYTOSIS What’s in a name? Many cases of non-clonal thrombocytosis are labeled “reactive.” But the biology behind these conditions differs substantially.

Curing an “incurable” lymphoma - are we there? Kudos to @mshadman @DrJFriedberg - and happy to be part of this study by the NCI NCTN SWOG Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy jamanetwork.com/journals/jamao…

An inspiring superb lecture by @DrHKantarjian⁩ on how to define cure in leukemia . ⁦@Myeloma_Society⁩ ⁦@COMyCongress⁩ ⁦@TheIACH⁩

#mmsm @Myeloma_Society #Cure Defining cure in hodgkin lymphoma While late relapse (could be the occurrence of a new Hodgkin lymphoma) can happen, this does not mean we cannot label patients as cured. How cure it though of in Hodgkin lymphoma

#mmsm @Myeloma_Society #Cure Finally the community agrees 👏👏👏

Interesting that so many of these cure assessments across diverse cancer types now routinely rely on #MRD. But what about the subset of patients with indolent diseases like #CLL and #FL that never require any Rx & yet expected to have persistent measurable disease? @MaurerStats Also, what about entities like ETV6-RUNX1 B-ALL where low level MRD persistence isn’t detrimental for relapse risk? Isolated single low level MRD measures in APL? Persistent CH clones after AML? Ancestral MGUS in MM and WM? Ancestral MBL in CLL? So, as our methods become increasingly sensitive, to more concretely define “cure”, I do wonder if we should ultimately be thinking about “MRD stability” and “uMRD durability” instead of using MRD status as a litmus test at a single, relatively arbitrary milestone (eg, EOT, 1, 2, 3, or 5 years)? I do also wonder how patient perspectives on “cure” and novel #PRO instruments could be better integrated to capture exactly when the enormous burdens that they carry are truly lifted during cancer #survivorship. @majorajay @PallawiTorkaMD @GitaThanaMD #lymsm

Our colleague, Basant Hamdy, a 2nd year intern at Kasr Al Ainy School of Medicine, suffered a major accident during her academic opportunity in Miami, Florida. She sustained a traumatic brain injury and is currently in critical condition in the ICU. gofund.me/fe6d8de7e